Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01239797 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 646
- Enrollment target
NCT01239797 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 646 participants.
The verdict
NCT01239797, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 646 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Dexamethasone (Oral)
- DRUG Dexamethasone (IV)
- BIOLOGICAL Elotuzumab (BMS-901608; HuLuc63)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2011-06-20 |
| Est. Completion | 2021-04-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01239797
The ClinicalTrials.gov registry entry for NCT01239797 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT01239797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01239797 about?
NCT01239797 is a clinical study titled "Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma". The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
What is the current status of trial NCT01239797?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 646 participants. The study started on 2011-06-20. Estimated completion is 2021-04-21.
What interventions are being tested in trial NCT01239797?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Dexamethasone (Oral) (DRUG), Dexamethasone (IV) (DRUG), Elotuzumab (BMS-901608; HuLuc63) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01239797?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.